Child Boards

[-] AUBAGIO (teriflunomide)

[-] AVONEX (interferon beta-1a)

[-] BETASERON (interferon beta-1b, Betaferon, Extavia)

[-] COPAXONE (glatiramer acetate)

[-] GILENYA (fingolimod, FTY720)

[-] GLATOPA (generic Copaxone - 20 mg/ml daily)

[-] LEMTRADA (Campath, alemtuzumab)

[-] NOVANTRONE (mitoxantrone)

[-] OCREVUS (ocrelizumab)

[-] PLEGRIDY (pegylated interferon beta-1a)

[-] REBIF (interferon beta-1a)

[-] TECFIDERA (dimethyl fumarate, BG-12, Fumaderm)

[-] TYSABRI (natalizumab)

[-] AMPYRA (dalfampridine)


(1/20) > >>


[2] Non-approved (off-label) treatments used for MS disease modification

[3] (Neurology Now) Guide to choosing a disease-modifying therapy for MS

[4] About Mavenclad and Mayzent in Canada

[5] PML in MS

[6] Ibudilast receives fast track designation--studied for SPMS and PPMS (MSAA Research News)

[7] (AAN poster) Effect of biotin in progressive MS

[8] (AAN abst.) Impact of Tysabri switch to moderate vs. high-efficacy DMT

[9] Mayzent (siponimod, BAF312) for active SPMS, RRMS


[0] Up one level

[#] Next page

Go to full version